Finance

Lists
JENBURPH:NSE
Jenburkt Pharmaceuticals Ltd
₹967.50
+1.08%
(+10.30) 1D
Sep 23, 9:32:39 AM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for JENBURPH...
Open
₹961.30
High
₹967.50
Low
₹961.30
Mkt. cap
4.65B
Avg. vol.
1.22K
Volume
14.00
P/E ratio
13.00
52-wk high
₹1,073.90
52-wk low
₹949.80
EPS
₹74.40
No. of employees
801
Open
₹961.30
High
₹967.50
Low
₹961.30
Mkt. cap
4.65B
Avg. vol.
1.22K
Volume
14.00
P/E ratio
13.00
52-wk high
₹1,073.90
52-wk low
₹949.80
EPS
₹74.40
No. of employees
801
About Jenburkt Pharmaceuticals Ltd
CEO-
Employees801
Founded1985
Headquarters-
SectorPharmaceutical industry
Last report
Aug 6, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
355.12M / -
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
455.58M
430.24M
446.32M
355.12M
Cost of goods sold
83.56M
87.89M
101.21M
63.22M
Cost of revenue
83.56M
87.89M
101.21M
63.22M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
139.32M
147.14M
95.15M
130.25M
Operating expense
248.41M
276.38M
191.98M
238.04M
Total operating expenses
331.97M
364.27M
293.19M
301.26M
Operating income
123.60M
65.97M
153.13M
53.86M
Other non operating income
20.79M
18.15M
-60.40M
15.13M
EBT including unusual items
143.32M
82.97M
137.08M
67.69M
EBT excluding unusual items
143.32M
82.97M
171.23M
67.69M
Income tax expense
41.69M
23.65M
28.59M
8.84M
Effective tax rate
29.09%
28.51%
20.85%
13.05%
Other operating expenses
101.64M
120.92M
88.74M
101.38M
Net income
101.63M
59.31M
108.49M
58.86M
Net profit margin
22.31%
13.79%
24.31%
16.57%
Earnings per share
-
-
-
-
Interest and investment income
-
-
57.47M
-
Interest expense
-1.07M
-1.16M
-392.00K
-1.30M
Net interest expenses
-1.07M
-1.16M
57.07M
-1.30M
Depreciation and amortization charges
7.44M
8.32M
8.09M
6.41M
EBITDA
130.94M
71.11M
158.72M
59.45M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps